Cardiorenal mechanisms of action of glucagon-like-peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors
Open accessThe DOI matches its Crossref record; 115 of the 115 references it cites were found in a registry or an index.
Abstract
Cardiovascular and renal outcome trials (CVOTs) for glucagon-like-peptide-1 receptor agonists (GLP1RA) and sodium-glucose cotransporter 2 inhibitors (SGLT2i) highlight new options for people with and without type 2 diabetes (T2D). Drugs within these classes reduce rates of major adverse cardiovascular events (MACE), with SGLT2i simultaneously attenuating decline in kidney function. SGLT2i reduce rates of heart failure in people with and without T2D, whereas GLP1RA lower rates of myocardial infarction and stroke in people with T2D with or without preexisting cardiovascular disease. Mechanistically, SGLT2 and the GLP-1 receptor are expressed at low levels in the heart, and within some blood vessels and immune cells, implying indirect mechanisms of action for the preservation of ventricular function, and reduction of atherosclerosis. SGLT2i likely preserve renal function through the alteration of glomerular hemodynamics. These two drug classes enable organ protection and reduced mortality in people with T2D and represent promising therapies for some people without T2D.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure
McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab368 · Cited by 13,344
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Anand, I. S., Bělohlávek, J., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1911303 · Cited by 7,140
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
Wiviott, S. D., Raz, I., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Silverman, M. G., Zelniker, T. A., Kuder, J. F., Murphy, S. A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812389 · Cited by 6,382
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189
Dapagliflozin in Patients with Chronic Kidney Disease
Heerspink, H. J. L., Stefánsson, B. V., Correa-Rotter, R., Chertow, G. M., Greene, T., Hou, F.-F., Mann, J. F. E., McMurray, J. J. V., Lindberg, M., Rossing, P., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2024816 · Cited by 5,618
Cardiovascular and renal outcomes with empagliflozin in heart failure
Packer, M., Anker, S. D., Butler, J., Filippatos, G., Pocock, S. J., Carson, P., Januzzi, J., Verma, S., Tsutsui, H., Brueckmann, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022190 · Cited by 5,206
Empagliflozin in heart failure with a preserved ejection fraction
Anker, S. D., Butler, J., Filippatos, G., Ferreira, J. P., Bocchi, E., Böhm, M., Brunner–La Rocca, H.-P., Choi, D.-J., Chopra, V., Chuquiure-Valenzuela, E., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107038 · Cited by 4,874
Research works printed but not linked: 150
- Nathan, 2006, Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes, Diabetes Care, 29, 1963, 10.2337/dc06-9912 · DOI · Paper page
- 1998, Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33), Lancet, 352, 837, 10.1016/S0140-6736(98)07019-6 · DOI · Paper page
- Holman, 2008, 10-year follow-up of intensive glucose control in type 2 diabetes, N. Engl. J. Med., 359, 1577, 10.1056/NEJMoa0806470 · DOI · Paper page
- Goldfine, 2008, Assessing the cardiovascular safety of diabetes therapies, N. Engl. J. Med., 359, 1092, 10.1056/NEJMp0805758 · DOI
- Siraj, 2020, Cardioprotective GLP-1 metabolite prevents ischemic cardiac injury by inhibiting mitochondrial trifunctional protein-α, J. Clin. Invest., 130, 1392, 10.1172/JCI99934 · DOI
- Worthington, 2018, Enteroendocrine cells-sensory sentinels of the intestinal environment and orchestrators of mucosal immunity, Mucosal Immunol., 11, 3, 10.1038/mi.2017.73 · DOI · Paper page
- Kahles, 2014, GLP-1 secretion is increased by inflammatory stimuli in an IL-6-dependent manner, leading to hyperinsulinemia and blood glucose lowering, Diabetes, 63, 3221, 10.2337/db14-0100 · DOI · Paper page
- Kahles, 2020, Glucagon-like peptide 1 levels predict cardiovascular risk in patients with acute myocardial infarction, Eur. Heart J., 41, 882, 10.1093/eurheartj/ehz728 · DOI · Paper page
- Elbaz-Greener, 2019, Endogenous glucagon-like peptide-1 system response is impaired during ST-elevation myocardial infarction in type 2 diabetes patients, Diabetes Obes. Metab., 21, 194, 10.1111/dom.13490 · DOI
- Ellingsgaard, 2011, Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L cells and alpha cells, Nat. Med., 17, 1481, 10.1038/nm.2513 · DOI · Paper page
- Ellingsgaard, 2020, GLP-1 secretion is regulated by IL-6 signalling: a randomised, placebo-controlled study, Diabetologia, 63, 362, 10.1007/s00125-019-05045-y · DOI
- Lebherz, 2016, Interleukin-6 predicts inflammation-induced increase of Glucagon-like peptide-1 in humans in response to cardiac surgery with association to parameters of glucose metabolism, Cardiovasc. Diabetol., 15, 21, 10.1186/s12933-016-0330-8 · DOI · Paper page
- Ussher, 2014, Cardiovascular actions of incretin-based therapies, Circ. Res., 114, 1788, 10.1161/CIRCRESAHA.114.301958 · DOI · Paper page
- Wallner, 2015, Exenatide exerts a PKA-dependent positive inotropic effect in human atrial myocardium: GLP-1R mediated effects in human myocardium, J. Mol. Cell. Cardiol., 89, 365, 10.1016/j.yjmcc.2015.09.018 · DOI
- Ussher, 2014, Inactivation of the cardiomyocyte glucagon-like peptide-1 receptor (GLP-1R) unmasks cardiomyocyte-independent GLP-1R-mediated cardioprotection, Mol. Metab., 3, 507, 10.1016/j.molmet.2014.04.009 · DOI
- Libby, 2015, Murine “model” monotheism: an iconoclast at the altar of mouse, Circ. Res., 117, 921, 10.1161/CIRCRESAHA.115.307523 · DOI · Paper page
- Pujadas, 2016, Vascular Biology of Glucagon Receptor Superfamily Peptides: Mechanistic and Clinical Relevance, Endocr. Rev., 37, 554, 10.1210/er.2016-1078 · DOI · Paper page
- Barragán, 1994, Changes in arterial blood pressure and heart rate induced by glucagon-like peptide-1-(7-36) amide in rats, Am. J. Physiol., 266, E459
- Ussher, 2012, Cardiovascular biology of the incretin system, Endocr. Rev., 33, 187, 10.1210/er.2011-1052 · DOI · Paper page
- Katout, 2014, Effect of GLP-1 mimetics on blood pressure and relationship to weight loss and glycemia lowering: results of a systematic meta-analysis and meta-regression, Am. J. Hypertens., 27, 130, 10.1093/ajh/hpt196 · DOI · Paper page
- Edwards, 1998, Subcutaneous glucagon-like peptide-1 (7-36) amide is insulinotropic and can cause hypoglycaemia in fasted healthy subjects, Clin. Sci. (Lond.), 95, 719, 10.1042/cs0950719 · DOI · Paper page
- Baggio, 2017, The autonomic nervous system and cardiac GLP-1 receptors control heart rate in mice, Mol. Metab., 6, 1339, 10.1016/j.molmet.2017.08.010 · DOI · Paper page
- Holt, 2020, PPG neurons in the nucleus of the solitary tract modulate heart rate but do not mediate GLP-1 receptor agonist-induced tachycardia in mice, Mol. Metab., 39, 101024, 10.1016/j.molmet.2020.101024 · DOI · Paper page
- Okerson, 2010, Effects of exenatide on systolic blood pressure in subjects with type 2 diabetes, Am. J. Hypertens., 23, 334, 10.1038/ajh.2009.245 · DOI · Paper page
- Rieg, 2012, Natriuretic effect by exendin-4, but not the DPP-4 inhibitor alogliptin, is mediated via the GLP-1 receptor and preserved in obese type 2 diabetic mice, Am. J. Physiol. Renal Physiol., 303, F963, 10.1152/ajprenal.00259.2012 · DOI · Paper page
- Asmar, 2021, The Renal Extraction and the Natriuretic Action of GLP-1 in Humans Depend on Interaction With the GLP-1 Receptor, J. Clin. Endocrinol. Metab., 106, e11, 10.1210/clinem/dgaa643 · DOI · Paper page
- von Scholten, 2017, The effect of liraglutide on renal function: a randomized clinical trial, Diabetes Obes. Metab., 19, 239, 10.1111/dom.12808 · DOI · Paper page
- Katsurada, 2020, GLP-1 mediated diuresis and natriuresis are blunted in heart failure and restored by selective afferent renal denervation, Cardiovasc. Diabetol., 19, 57, 10.1186/s12933-020-01029-0 · DOI
- Hsieh, 2010, The glucagon-like peptide 1 receptor is essential for postprandial lipoprotein synthesis and secretion in hamsters and mice, Diabetologia, 53, 552, 10.1007/s00125-009-1611-5 · DOI · Paper page
- Vergès, 2018, Liraglutide Reduces Postprandial Hyperlipidemia by Increasing ApoB48 (Apolipoprotein B48) Catabolism and by Reducing ApoB48 Production in Patients With Type 2 Diabetes Mellitus, Arterioscler. Thromb. Vasc. Biol., 38, 2198, 10.1161/ATVBAHA.118.310990 · DOI · Paper page
- Farr, 2015, Central Nervous System Regulation of Intestinal Lipoprotein Metabolism by Glucagon-Like Peptide-1 via a Brain-Gut Axis, Arterioscler. Thromb. Vasc. Biol., 35, 1092, 10.1161/ATVBAHA.114.304873 · DOI · Paper page
- Burmeister, 2012, Acute activation of central GLP-1 receptors enhances hepatic insulin action and insulin secretion in high-fat-fed, insulin resistant mice, Am. J. Physiol. Endocrinol. Metab., 302, E334, 10.1152/ajpendo.00409.2011 · DOI · Paper page
- He, 2019, Gut intraepithelial T cells calibrate metabolism and accelerate cardiovascular disease, Nature, 566, 115, 10.1038/s41586-018-0849-9 · DOI · Paper page
- Kelly, 2012, Effects of exenatide vs. metformin on endothelial function in obese patients with pre-diabetes: a randomized trial, Cardiovasc. Diabetol., 11, 64, 10.1186/1475-2840-11-64 · DOI · Paper page
- Cameron-Vendrig, 2016, Glucagon-like peptide-1 receptor activation attenuates platelet aggregation and thrombosis, Diabetes, 65, 1714, 10.2337/db15-1141 · DOI · Paper page
- Igoillo-Esteve, 2020, Exenatide induces frataxin expression and improves mitochondrial function in Friedreich ataxia, JCI Insight, 5, 134221, 10.1172/jci.insight.134221 · DOI
- Sternkopf, 2020, Native, Intact Glucagon-Like Peptide 1 Is a Natural Suppressor of Thrombus Growth Under Physiological Flow Conditions, Arterioscler. Thromb. Vasc. Biol., 40, e65, 10.1161/ATVBAHA.119.313645 · DOI · Paper page
- Barale, 2019, Hypercholesterolemia impairs the Glucagon-like peptide 1 action on platelets: effects of a lipid-lowering treatment with simvastatin, Thromb. Res., 180, 74, 10.1016/j.thromres.2019.06.010 · DOI
- Lønborg, 2012, Exenatide reduces final infarct size in patients with ST-segment-elevation myocardial infarction and short-duration of ischemia, Circ. Cardiovasc. Interv., 5, 288, 10.1161/CIRCINTERVENTIONS.112.968388 · DOI · Paper page
- Roos, 2016, No benefit of additional treatment with exenatide in patients with an acute myocardial infarction, Int. J. Cardiol., 220, 809, 10.1016/j.ijcard.2016.06.283 · DOI · Paper page
- Giblett, 2019, The role of Glucagon-Like Peptide 1 Loading on periprocedural myocardial infarction During elective PCI (GOLD-PCI study): A randomized, placebo-controlled trial, Am. Heart J., 215, 41, 10.1016/j.ahj.2019.05.013 · DOI
- Chen, 2015, Effects of liraglutide on left ventricular function in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention, Am. Heart J., 170, 845, 10.1016/j.ahj.2015.07.014 · DOI
- Lønborg, 2012, Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction, Eur. Heart J., 33, 1491, 10.1093/eurheartj/ehr309 · DOI · Paper page
- Chen, 2016, Effects of Liraglutide on Reperfusion Injury in Patients With ST-Segment-Elevation Myocardial Infarction, Circ. Cardiovasc. Imaging, 9, e005146, 10.1161/CIRCIMAGING.116.005146 · DOI · Paper page
- Holman, 2017, Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes, N. Engl. J. Med., 377, 1228, 10.1056/NEJMoa1612917 · DOI · Paper page
- Gerstein, 2019, Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial, Lancet, 394, 121, 10.1016/S0140-6736(19)31149-3 · DOI · Paper page
- Husain, 2019, Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes, N. Engl. J. Med., 381, 841, 10.1056/NEJMoa1901118 · DOI · Paper page
- Clarke, 2018, GLP-1 Is a Coronary Artery Vasodilator in Humans, J. Am. Heart Assoc., 7, e010321, 10.1161/JAHA.118.010321 · DOI
- Nikolaidis, 2004, Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy, Circulation, 110, 955, 10.1161/01.CIR.0000139339.85840.DD · DOI · Paper page
- Bao, 2011, Albiglutide, a long lasting glucagon-like peptide-1 analog, protects the rat heart against ischemia/reperfusion injury: evidence for improving cardiac metabolic efficiency, PLoS ONE, 6, e23570, 10.1371/journal.pone.0023570 · DOI · Paper page
- Almutairi, 2021, The GLP-1 Receptor Agonist Liraglutide Increases Myocardial Glucose Oxidation Rates via Indirect Mechanisms and Mitigates Experimental Diabetic Cardiomyopathy, Can. J. Cardiol., 37, 140
- Filion, 2016, A Multicenter Observational Study of Incretin-based Drugs and Heart Failure, N. Engl. J. Med., 374, 1145, 10.1056/NEJMoa1506115 · DOI · Paper page
- Nielsen, 2020, The impact of the glucagon-like peptide-1 receptor agonist liraglutide on natriuretic peptides in heart failure patients with reduced ejection fraction with and without type 2 diabetes, Diabetes Obes. Metab., 22, 2141, 10.1111/dom.14135 · DOI
- Zinman, 2018, Hypoglycemia, Cardiovascular Outcomes, and Death: The LEADER Experience, Diabetes Care, 41, 1783, 10.2337/dc17-2677 · DOI · Paper page
- Cherney, 2018, Pooled analysis of Phase III trials indicate contrasting influences of renal function on blood pressure, body weight, and HbA1c reductions with empagliflozin, Kidney Int., 93, 231, 10.1016/j.kint.2017.06.017 · DOI · Paper page
- Thomas, 2018, The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure, Diabetologia, 61, 2098, 10.1007/s00125-018-4669-0 · DOI · Paper page
- Neal, 2017, Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes, N. Engl. J. Med., 377, 644, 10.1056/NEJMoa1611925 · DOI · Paper page
- Cherney, 2014, Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus, Circulation, 129, 587, 10.1161/CIRCULATIONAHA.113.005081 · DOI · Paper page
- Perkins, 2014, Sodium-glucose cotransporter 2 inhibition and glycemic control in type 1 diabetes: results of an 8-week open-label proof-of-concept trial, Diabetes Care, 37, 1480, 10.2337/dc13-2338 · DOI · Paper page
- Bhatt, 2021, Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease, N. Engl. J. Med., 384, 129, 10.1056/NEJMoa2030186 · DOI · Paper page
- Cherney, 2021, Gradient of Risk and Associations With Cardiovascular Efficacy of Ertugliflozin by Measures of Kidney Function: Observations From VERTIS CV, Circulation, 143, 602, 10.1161/CIRCULATIONAHA.120.051901 · DOI · Paper page
- Cherney, 2021, Kidney outcomes using a sustained ≥40% decline in eGFR: a meta-analysis of SGLT2 inhibitor trials, Clin. Cardiol., 44, 1139, 10.1002/clc.23665 · DOI
- Cherney, 2021, Effects of ertugliflozin on kidney composite outcomes, renal function and albuminuria in patients with type 2 diabetes mellitus: an analysis from the randomised VERTIS CV trial, Diabetologia, 64, 1256, 10.1007/s00125-021-05407-5 · DOI · Paper page
- van Raalte, 2021, Importance of standardizing renal outcomes in clinical trials: illustration by recent sodium glucose cotransporter 2 inhibitor studies, Kidney Int., 99, 768, 10.1016/j.kint.2020.12.006 · DOI
- Cherney, 2021, DAPA-CKD: The Beginning of a New Era in Renal Protection, JACC Basic Transl. Sci., 6, 74, 10.1016/j.jacbts.2020.10.005 · DOI
- Neuen, 2019, Sodium-glucose cotransporter inhibitors in type 2 diabetes: thinking beyond glucose lowering, CMAJ, 191, E1128, 10.1503/cmaj.190047 · DOI
- Perkins, 2016, No Need to Sugarcoat the Message: Is Cardiovascular Risk Reduction From SGLT2 Inhibition Related to Natriuresis?, Am. J. Kidney Dis., 68, 349, 10.1053/j.ajkd.2016.03.410 · DOI
- Verma, 2017, The Metabolodiuretic Promise of Sodium-Dependent Glucose Cotransporter 2 Inhibition: The Search for the Sweet Spot in Heart Failure, JAMA Cardiol., 2, 939, 10.1001/jamacardio.2017.1891 · DOI · Paper page
- Srinivasan Sridhar, 2019, Renal SGLT mRNA expression in human health and disease: a study in two cohorts, Am. J. Physiol. Renal Physiol., 317, F1224, 10.1152/ajprenal.00370.2019 · DOI
- Barnett, 2014, Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial, Lancet Diabetes Endocrinol., 2, 369, 10.1016/S2213-8587(13)70208-0 · DOI · Paper page
- Cherney, 2020, Effects of ertugliflozin on renal function over 104 weeks of treatment: a post hoc analysis of two randomised controlled trials, Diabetologia, 63, 1128, 10.1007/s00125-020-05133-4 · DOI · Paper page
- Cooper, 2019, Glucose Control and the Effect of Empagliflozin on Kidney Outcomes in Type 2 Diabetes: An Analysis From the EMPA-REG OUTCOME Trial, Am. J. Kidney Dis., 74, 713, 10.1053/j.ajkd.2019.03.432 · DOI
- Lawler, 2021, Changes in Cardiovascular Biomarkers Associated With the Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor Ertugliflozin in Patients With Chronic Kidney Disease and Type 2 Diabetes, Diabetes Care, 44, e45, 10.2337/dc20-2265 · DOI
- León Jiménez, 2018, Antihyperglycemic agents as novel natriuretic therapies in diabetic kidney disease, Am. J. Physiol. Renal Physiol., 315, F1406, 10.1152/ajprenal.00384.2017 · DOI
- Lytvyn, 2020, SGLT2 inhibition increases serum copeptin in young adults with type 1 diabetes, Diabetes Metab., 46, 203, 10.1016/j.diabet.2019.11.006 · DOI
- Bjornstad, 2018, Acute Effect of Empagliflozin on Fractional Excretion of Sodium and eGFR in Youth With Type 2 Diabetes, Diabetes Care, 41, e129, 10.2337/dc18-0394 · DOI
- Neuwirt, 2019, Tubuloglomerular Feedback in Renal Glucosuria: Mimicking Long-term SGLT-2 Inhibitor Therapy, Kidney Med., 2, 76, 10.1016/j.xkme.2019.09.006 · DOI
- Rajasekeran, 2017, Urinary adenosine excretion in type 1 diabetes, Am. J. Physiol. Renal Physiol., 313, F184, 10.1152/ajprenal.00043.2017 · DOI · Paper page
- Skrtić, 2014, Characterisation of glomerular haemodynamic responses to SGLT2 inhibition in patients with type 1 diabetes and renal hyperfiltration, Diabetologia, 57, 2599, 10.1007/s00125-014-3396-4 · DOI · Paper page
- Sochett, 2006, Impact of renin angiotensin system modulation on the hyperfiltration state in type 1 diabetes, J. Am. Soc. Nephrol., 17, 1703, 10.1681/ASN.2005080872 · DOI · Paper page
- Rajasekeran, 2018, Dapagliflozin in focal segmental glomerulosclerosis: a combined human-rodent pilot study, Am. J. Physiol. Renal Physiol., 314, F412, 10.1152/ajprenal.00445.2017 · DOI · Paper page
- Mayer, 2019, Analysis from the EMPA-REG OUTCOME® trial indicates empagliflozin may assist in preventing the progression of chronic kidney disease in patients with type 2 diabetes irrespective of medications that alter intrarenal hemodynamics, Kidney Int., 96, 489, 10.1016/j.kint.2019.02.033 · DOI · Paper page
- Cherney, 2016, Use of Sodium Glucose Cotransporter 2 Inhibitors in the Hands of Cardiologists: With Great Power Comes Great Responsibility, Circulation, 134, 1915, 10.1161/CIRCULATIONAHA.116.024764 · DOI · Paper page
- Dubrofsky, 2020, Sodium-Glucose Cotransporter-2 Inhibitors in Nephrology Practice: A Narrative Review, Can. J. Kidney Health Dis., 7, 10.1177/2054358120935701 · DOI
- Vinovskis, 2020, Relative Hypoxia and Early Diabetic Kidney Disease in Type 1 Diabetes, Diabetes, 69, 2700, 10.2337/db20-0457 · DOI
- van Raalte, 2018, Sodium glucose cotransporter 2 inhibition and renal ischemia: implications for future clinical trials, Kidney Int., 94, 459, 10.1016/j.kint.2018.05.026 · DOI · Paper page
- Layton, 2015, Modeling oxygen consumption in the proximal tubule: effects of NHE and SGLT2 inhibition, Am. J. Physiol. Renal Physiol., 308, F1343, 10.1152/ajprenal.00007.2015 · DOI · Paper page
- Layton, 2016, Predicted consequences of diabetes and SGLT inhibition on transport and oxygen consumption along a rat nephron, Am. J. Physiol. Renal Physiol., 310, F1269, 10.1152/ajprenal.00543.2015 · DOI
- Tanaka, 2018, Sodium-glucose cotransporter 2 inhibition normalizes glucose metabolism and suppresses oxidative stress in the kidneys of diabetic mice, Kidney Int., 94, 912, 10.1016/j.kint.2018.04.025 · DOI · Paper page
- Bessho, 2019, Hypoxia-inducible factor-1α is the therapeutic target of the SGLT2 inhibitor for diabetic nephropathy, Sci. Rep., 9, 14754, 10.1038/s41598-019-51343-1 · DOI · Paper page
- Zapata-Morales, 2014, Hypoxia-inducible factor-1α (HIF-1α) protein diminishes sodium glucose transport 1 (SGLT1) and SGLT2 protein expression in renal epithelial tubular cells (LLC-PK1) under hypoxia, J. Biol. Chem., 289, 346, 10.1074/jbc.M113.526814 · DOI · Paper page
- Nassif, 2021, Empagliflozin Effects on Pulmonary Artery Pressure in Patients With Heart Failure: Results From the EMBRACE-HF Trial, Circulation, 143, 1673, 10.1161/CIRCULATIONAHA.120.052503 · DOI · Paper page
- Lytvyn, 2017, Sodium Glucose Cotransporter-2 Inhibition in Heart Failure: Potential Mechanisms, Clinical Applications, and Summary of Clinical Trials, Circulation, 136, 1643, 10.1161/CIRCULATIONAHA.117.030012 · DOI · Paper page
- Wang, 2017, SGLT2 Protein Expression Is Increased in Human Diabetic Nephropathy: SGLT2 Protein Inhibition Decreases Renal Lipid Accumulation, Inflammation, and the Development of Nephropathy in Diabetic Mice, J. Biol. Chem., 292, 5335, 10.1074/jbc.M117.779520 · DOI · Paper page
- Tahara, 2018, Prevention of progression of diabetic nephropathy by the SGLT2 inhibitor ipragliflozin in uninephrectomized type 2 diabetic mice, Eur. J. Pharmacol., 830, 68, 10.1016/j.ejphar.2018.04.024 · DOI
- Ishibashi, 2016, ). Tofogliflozin, A Highly Selective Inhibitor of SGLT2 Blocks Proinflammatory and Proapoptotic Effects of Glucose Overload on Proximal Tubular Cells Partly by Suppressing Oxidative Stress Generation, Horm. Metab. Res., 48, 191
- Das, 2020, Empagliflozin reduces high glucose-induced oxidative stress and miR-21-dependent TRAF3IP2 induction and RECK suppression, and inhibits human renal proximal tubular epithelial cell migration and epithelial-to-mesenchymal transition, Cell. Signal., 68, 109506, 10.1016/j.cellsig.2019.109506 · DOI
- Abdel-Wahab, 2018, Renal protective effect of SGLT2 inhibitor dapagliflozin alone and in combination with irbesartan in a rat model of diabetic nephropathy, Biomed. Pharmacother., 103, 59, 10.1016/j.biopha.2018.03.176 · DOI
- Kopecky, 2019, Molecular regulation of the renin-angiotensin system by sodium-glucose cotransporter 2 inhibition in type 1 diabetes mellitus, Diabetologia, 62, 1090, 10.1007/s00125-019-4871-8 · DOI
- Dekkers, 2018, Effects of the SGLT-2 inhibitor dapagliflozin on glomerular and tubular injury markers, Diabetes Obes. Metab., 20, 1988, 10.1111/dom.13301 · DOI · Paper page
- Jaikumkao, 2018, Dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, slows the progression of renal complications through the suppression of renal inflammation, endoplasmic reticulum stress and apoptosis in prediabetic rats, Diabetes Obes. Metab., 20, 2617, 10.1111/dom.13441 · DOI
- Kim, 2019, Effects of empagliflozin on nondiabetic salt-sensitive hypertension in uninephrectomized rats, Hypertens. Res., 42, 1905, 10.1038/s41440-019-0326-3 · DOI
- Opingari, 2020, The impact of empagliflozin on kidney injury molecule-1: a subanalysis of the Effects of Empagliflozin on Cardiac Structure, Function, and Circulating Biomarkers in Patients with Type 2 Diabetes CardioLink-6 Trial, Nephrol. Dial. Transplant., 35, 895, 10.1093/ndt/gfz294 · DOI
- Chang, 2016, Dapagliflozin, SGLT2 Inhibitor, Attenuates Renal Ischemia-Reperfusion Injury, PLoS ONE, 11, e0158810, 10.1371/journal.pone.0158810 · DOI · Paper page
- Iskander, 2020, Use of sodium-glucose cotransporter-2 inhibitors and risk of acute kidney injury in older adults with diabetes: a population-based cohort study, CMAJ, 192, E351, 10.1503/cmaj.191283 · DOI · Paper page
- Kraus, 2021, Characterization and implications of the initial estimated glomerular filtration rate ‘dip’ upon sodium-glucose cotransporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOME trial, Kidney Int., 99, 750, 10.1016/j.kint.2020.10.031 · DOI · Paper page
- Rajasekeran, 2017, Use of Canagliflozin in Kidney Transplant Recipients for the Treatment of Type 2 Diabetes: A Case Series, Diabetes Care, 40, e75, 10.2337/dc17-0237 · DOI
- Tuttle, 2020, Sodium Glucose Cotransporter 2 Inhibition Heralds a Call-to-Action for Diabetic Kidney Disease, Clin. J. Am. Soc. Nephrol., 15, 285, 10.2215/CJN.07730719 · DOI
- Tuttle, 2021, Therapeutic transformation for diabetic kidney disease, Kidney Int., 99, 301, 10.1016/j.kint.2020.10.003 · DOI
- Sridhar, 2021, Cardiometabolic and Kidney Protection in Kidney Transplant Recipients with Diabetes: Mechanisms, Clinical Applications, and Summary of Clinical Trials, Transplantation
- Berg, 2021, Time to Clinical Benefit of Dapagliflozin and Significance of Prior Heart Failure Hospitalization in Patients With Heart Failure With Reduced Ejection Fraction, JAMA Cardiol., 6, 499, 10.1001/jamacardio.2020.7585 · DOI · Paper page
- Brown, 2020, A randomized controlled trial of dapagliflozin on left ventricular hypertrophy in people with type two diabetes: the DAPA-LVH trial, Eur. Heart J., 41, 3421, 10.1093/eurheartj/ehaa419 · DOI · Paper page
- Verma, 2019, Empagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Left Ventricular Hypertrophy: A Subanalysis of the EMPA-REG OUTCOME Trial, Diabetes Care, 42, e42, 10.2337/dc18-1959 · DOI
- Lee, 2021, Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF), Circulation, 143, 516, 10.1161/CIRCULATIONAHA.120.052186 · DOI · Paper page
- Omar, 2021, Associations of Empagliflozin With Left Ventricular Volumes, Mass, and Function in Patients With Heart Failure and Reduced Ejection Fraction: A Substudy of the Empire HF Randomized Clinical Trial, JAMA Cardiol., 6, 836, 10.1001/jamacardio.2020.6827 · DOI · Paper page
- Santos-Gallego, 2021, Empagliflozin Ameliorates Diastolic Dysfunction and Left Ventricular Fibrosis/Stiffness in Nondiabetic Heart Failure: A Multimodality Study, JACC Cardiovasc. Imaging, 14, 393, 10.1016/j.jcmg.2020.07.042 · DOI · Paper page
- Lee, 2021, Sodium/glucose Co-Transporter 2 Inhibitor, Empagliflozin, Alleviated Transient Expression of SGLT2 after Myocardial Infarction, Korean Circ. J., 51, 251, 10.4070/kcj.2020.0303 · DOI
- Singh, 2020, Dapagliflozin Versus Placebo on Left Ventricular Remodeling in Patients With Diabetes and Heart Failure: The REFORM Trial, Diabetes Care, 43, 1356, 10.2337/dc19-2187 · DOI · Paper page
- Byrne, 2017, Empagliflozin Prevents Worsening of Cardiac Function in an Experimental Model of Pressure Overload-Induced Heart Failure, JACC Basic Transl. Sci., 2, 347, 10.1016/j.jacbts.2017.07.003 · DOI · Paper page
- Jensen, 2021, Effects of empagliflozin on estimated extracellular volume, estimated plasma volume, and measured glomerular filtration rate in patients with heart failure (Empire HF Renal): a prespecified substudy of a double-blind, randomised, placebo-controlled trial, Lancet Diabetes Endocrinol., 9, 106, 10.1016/S2213-8587(20)30382-X · DOI
- Boorsma, 2021, Effects of empagliflozin on renal sodium and glucose handling in patients with acute heart failure, Eur. J. Heart Fail., 23, 68, 10.1002/ejhf.2066 · DOI
- Mordi, 2020, Renal and Cardiovascular Effects of SGLT2 Inhibition in Combination With Loop Diuretics in Patients With Type 2 Diabetes and Chronic Heart Failure: The RECEDE-CHF Trial, Circulation, 142, 1713, 10.1161/CIRCULATIONAHA.120.048739 · DOI · Paper page
- Anand, 2003, Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT), Circulation, 107, 1278, 10.1161/01.CIR.0000054164.99881.00 · DOI · Paper page
- Damman, 2020, Randomized, double-blind, placebo-controlled, multicentre pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure (EMPA-RESPONSE-AHF), Eur. J. Heart Fail., 22, 713, 10.1002/ejhf.1713 · DOI · Paper page
- Mustroph, 2018, Empagliflozin reduces Ca/calmodulin-dependent kinase II activity in isolated ventricular cardiomyocytes, ESC Heart Fail., 5, 642, 10.1002/ehf2.12336 · DOI · Paper page
- Packer, 2017, Activation and Inhibition of Sodium-Hydrogen Exchanger Is a Mechanism That Links the Pathophysiology and Treatment of Diabetes Mellitus With That of Heart Failure, Circulation, 136, 1548, 10.1161/CIRCULATIONAHA.117.030418 · DOI · Paper page
- von Lewinski, 2010, Glucose-transporter-mediated positive inotropic effects in human myocardium of diabetic and nondiabetic patients, Metabolism, 59, 1020, 10.1016/j.metabol.2009.10.025 · DOI
- Baartscheer, 2017, Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+/H+ exchanger in rats and rabbits, Diabetologia, 60, 568, 10.1007/s00125-016-4134-x · DOI · Paper page
- Uthman, 2018, Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na+/H+ exchanger, lowering of cytosolic Na+ and vasodilation, Diabetologia, 61, 722, 10.1007/s00125-017-4509-7 · DOI · Paper page
- Philippaert, 2021, Cardiac Late Sodium Channel Current Is a Molecular Target for the Sodium/Glucose Cotransporter 2 Inhibitor Empagliflozin, Circulation, 143, 2188, 10.1161/CIRCULATIONAHA.121.053350 · DOI · Paper page
- Byrne, 2020, Empagliflozin Blunts Worsening Cardiac Dysfunction Associated With Reduced NLRP3 (Nucleotide-Binding Domain-Like Receptor Protein 3) Inflammasome Activation in Heart Failure, Circ. Heart Fail., 13, e006277, 10.1161/CIRCHEARTFAILURE.119.006277 · DOI · Paper page
- Lehrke, 2019, SGLT2 Inhibition: Changing What Fuels the Heart, J. Am. Coll. Cardiol., 73, 1945, 10.1016/j.jacc.2019.02.023 · DOI
- Verma, 2018, Empagliflozin Increases Cardiac Energy Production in Diabetes: Novel Translational Insights Into the Heart Failure Benefits of SGLT2 Inhibitors, JACC Basic Transl. Sci., 3, 575, 10.1016/j.jacbts.2018.07.006 · DOI · Paper page
- Santos-Gallego, 2019, Empagliflozin Ameliorates Adverse Left Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial Energetics, J. Am. Coll. Cardiol., 73, 1931, 10.1016/j.jacc.2019.01.056 · DOI · Paper page
- Batzias, 2018, Effects of Newer Antidiabetic Drugs on Endothelial Function and Arterial Stiffness: A Systematic Review and Meta-Analysis, J. Diabetes Res., 2018, 1232583
- Croteau, 2021, Effects of Sodium-Glucose Linked Transporter 2 Inhibition With Ertugliflozin on Mitochondrial Function, Energetics, and Metabolic Gene Expression in the Presence and Absence of Diabetes Mellitus in Mice, J. Am. Heart Assoc., 10, e019995, 10.1161/JAHA.120.019995 · DOI · Paper page
- Li, 2021, Direct Cardiac Actions of the Sodium Glucose Co-Transporter 2 Inhibitor Empagliflozin Improve Myocardial Oxidative Phosphorylation and Attenuate Pressure-Overload Heart Failure, J. Am. Heart Assoc., 10, e018298, 10.1161/JAHA.120.018298 · DOI
- Aberle, 2020, Dapagliflozin effects on haematocrit, red blood cell count and reticulocytes in insulin-treated patients with type 2 diabetes, Sci. Rep., 10, 22396, 10.1038/s41598-020-78734-z · DOI
- Ghanim, 2020, Dapagliflozin Suppresses Hepcidin And Increases Erythropoiesis, J. Clin. Endocrinol. Metab., 105, dgaa057, 10.1210/clinem/dgaa057 · DOI · Paper page
- Day, 2020, The SGLT2 inhibitor canagliflozin suppresses lipid synthesis and interleukin-1 beta in ApoE deficient mice, Biochem. J., 477, 2347, 10.1042/BCJ20200278 · DOI
- Nakatsu, 2017, The SGLT2 Inhibitor Luseogliflozin Rapidly Normalizes Aortic mRNA Levels of Inflammation-Related but Not Lipid-Metabolism-Related Genes and Suppresses Atherosclerosis in Diabetic ApoE KO Mice, Int. J. Mol. Sci., 18, 1704, 10.3390/ijms18081704 · DOI · Paper page
- Sakurai, 2020, Empagliflozin decreases the plasma concentration of plasminogen activator inhibitor-1 (PAI-1) in patients with type 2 diabetes: Association with improvement of fibrinolysis, J. Diabetes Complications, 34, 107703, 10.1016/j.jdiacomp.2020.107703 · DOI
- Sayour, 2019, Acute canagliflozin treatment protects against in vivo myocardial ischemia-reperfusion injury in non-diabetic male rats and enhances endothelium-dependent vasorelaxation, J. Transl. Med., 17, 127, 10.1186/s12967-019-1881-8 · DOI · Paper page
- Nasiri-Ansari, 2018, Canagliflozin attenuates the progression of atherosclerosis and inflammation process in APOE knockout mice, Cardiovasc. Diabetol., 17, 106, 10.1186/s12933-018-0749-1 · DOI · Paper page
- Ganbaatar, 2020, Empagliflozin ameliorates endothelial dysfunction and suppresses atherogenesis in diabetic apolipoprotein E-deficient mice, Eur. J. Pharmacol., 875, 173040, 10.1016/j.ejphar.2020.173040 · DOI · Paper page
- Behnammanesh, 2020, Canagliflozin inhibits vascular smooth muscle cell proliferation and migration: role of heme oxygenase-1, Redox Biol., 32, 101527, 10.1016/j.redox.2020.101527 · DOI
- Xu, 2018, Canagliflozin exerts anti-inflammatory effects by inhibiting intracellular glucose metabolism and promoting autophagy in immune cells, Biochem. Pharmacol., 152, 45, 10.1016/j.bcp.2018.03.013 · DOI · Paper page
- Maddox, 2021, J. Am. Coll. Cardiol., 77, 772, 10.1016/j.jacc.2020.11.022 · DOI · Paper page
- Solomon, 2021, Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial, Eur. J. Heart Fail., 23, 1217, 10.1002/ejhf.2249 · DOI · Paper page
- Tromp, 2021, Sodium-glucose co-transporter 2 inhibition in patients hospitalized for acute decompensated heart failure: rationale for and design of the EMPULSE trial, Eur. J. Heart Fail., 23, 826, 10.1002/ejhf.2137 · DOI · Paper page
Cited by
Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action
Ussher, J. R., & Drucker, D. J. (2023) · Nature Reviews Cardiology · doi:10.1038/s41569-023-00849-3 · Cited by 577
Self-citationThe cardio-renal-metabolic connection: a review of the evidence
Marassi, M., & Fadini, G. P. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01937-x · Cited by 386
Beyond the pancreas: contrasting cardiometabolic actions of GIP and GLP1
Hammoud, R., & Drucker, D. J. (2023) · Nature Reviews Endocrinology · doi:10.1038/s41574-022-00783-3 · Cited by 244
“The cardiovascular benefits of GLP1RAs become evident within 12–24 months of trial initiation 130 .”
Self-citationThe expanding incretin universe: from basic biology to clinical translation
Drucker, D. J., & Holst, J. J. (2023) · Diabetologia · doi:10.1007/s00125-023-05906-7 · Cited by 243
“However, the temporal reduction of MACE events in people with type 2 diabetes treated with GLP-1RA takes longer, becoming evident from 12 to 18 months from trial initiation [115, 116].”
Self-citationSolomon, S. D., Ostrominski, J. W., Wang, X., Shah, S. J., Borlaug, B. A., Butler, J., Davies, M. J., Kitzman, D. W., Verma, S., Abildstrøm, S. Z., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.08.021 · Cited by 154
Metadata
- Authors
- Cherney, D. Z. I., Udell, J. A., & Drucker, D. J.
- Venue
- Med
- Publisher
- Elsevier BV
- Published
- 2021-11
- Volume
- 2
- Issue
- 11
- Pages
- 1203-1230
- ISSN
- 2666-6340 (ISSN-L)
- OpenAlex
- W3213645653
- Cited by
- 50
- References
- 115
- FWCI
- 4.83
- Type
- journal article
- Language
- en
- Open access
- bronze
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 376 d)
- doi.org/10.15223/policy-017 (stm-asf)
- doi.org/10.15223/policy-037 (stm-asf)
- doi.org/10.15223/policy-012 (stm-asf)
- doi.org/10.15223/policy-029 (stm-asf)
- doi.org/10.15223/policy-004 (stm-asf)
- Funders
- Novartis
- Sanofi
- Janssen Pharmaceuticals
- Diabetes Canada
- Women's College Research Institute
- Merck
- Ministry of Colleges and Universities (ER15-11-037)
- Amgen
- Heart and Stroke Foundation of Canada
- Pfizer
- Novo Nordisk
- AstraZeneca
- Department of Medicine, University of Toronto
- Bayer
- Canadian Institutes of Health Research
- CIHR INMD (154321)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cardiorenal mechanisms of action of glucagon-like-peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors. https://app.cochat.ai/papers/10.1016/j.medj.2021.10.004
- The paper
- Cherney, D. Z. I., Udell, J. A., & Drucker, D. J. (2021). Cardiorenal mechanisms of action of glucagon-like-peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors. Med. https://doi.org/10.1016/j.medj.2021.10.004
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.